Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Baylor College of Medicine
• Treatments: Dexmedetomidine

Criteria

Exclusion Criteria:

1. Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation

2. History of difficult intubation or ventilation

3. Airway malformation

4. Congenital heart disease

5. Cardiac arrhythmias

6. Central nervous system disease, including developmental delay, cerebral palsy, or seizure disorder

7. History of or family history of malignant hyperthermia

8. Electrolyte disorders

9. Gastrointestinal disease

10. Hepatic dysfunction

11. Renal dysfunction

12. Metabolic disease, such as diabetes

13. Obesity, defined as a body mass index greater than the 95% percentile for age

14. Preterm infant (less than 37 weeks gestational age) 15. Use of any medications (anticonvulsants, opioids, benzodiazepines, antibiotics, antihistamines drugs that induce hepatic enzymes) that may affect MAC.

Inclusion Criteria

All patients age 1 month- 3 years presenting for surgery.